{"id":"https://openalex.org/W2122950669","doi":"https://doi.org/10.1136/annrheumdis-2014-205847","title":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","display_name":"Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme","publication_year":2015,"publication_date":"2015-04-23","ids":{"openalex":"https://openalex.org/W2122950669","doi":"https://doi.org/10.1136/annrheumdis-2014-205847","mag":"2122950669","pmid":"https://pubmed.ncbi.nlm.nih.gov/25902789","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4853586"},"language":"en","primary_location":{"id":"doi:10.1136/annrheumdis-2014-205847","doi":"https://doi.org/10.1136/annrheumdis-2014-205847","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2014-205847","pdf_url":"https://ard.bmj.com/content/annrheumdis/75/5/831.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"volume":null,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://ard.bmj.com/content/annrheumdis/75/5/831.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5000754711","display_name":"Jeffrey R. Curtis","orcid":"https://orcid.org/0000-0002-8907-8976","observed_orcids":["https://orcid.org/0000-0002-8907-8976"]},"institutions":[{"id":"https://openalex.org/I32389192","display_name":"University of Alabama at Birmingham","ror":"https://ror.org/008s83205","country_code":"US","type":"education","lineage":["https://openalex.org/I32389192"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeffrey R Curtis","raw_affiliation_strings":["The University of Alabama at Birmingham, Birmingham, Alabama, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"The University of Alabama at Birmingham, Birmingham, Alabama, USA","institution_ids":["https://openalex.org/I32389192"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024958150","display_name":"Eun Bong Lee","orcid":"https://orcid.org/0000-0003-0703-1208","observed_orcids":["https://orcid.org/0000-0003-0703-1208","https://orcid.org/0000-0001-6975-8627"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Eun Bong Lee","raw_affiliation_strings":["Seoul National University College of Medicine, Seoul, Republic of Korea","Seoul National University College of Medicine, Seoul, Republic of Korea#TAB#"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Seoul National University College of Medicine, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I139264467"]},{"raw_affiliation_string":"Seoul National University College of Medicine, Seoul, Republic of Korea#TAB#","institution_ids":["https://openalex.org/I139264467"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111528859","display_name":"Irina V Kaplan","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Irina V Kaplan","raw_affiliation_strings":["Pfizer Inc, Groton, Connecticut, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Groton, Connecticut, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Kenneth Kwok","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth Kwok","raw_affiliation_strings":["Pfizer Inc, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New York, New York, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047193011","display_name":"Jamie L. Geier","orcid":"https://orcid.org/0000-0002-2059-2117","observed_orcids":["https://orcid.org/0000-0002-2059-2117"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jamie Geier","raw_affiliation_strings":["Pfizer Inc, New York, New York, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, New York, New York, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067393049","display_name":"Birgitta Benda","orcid":"https://orcid.org/0000-0001-8712-2251","observed_orcids":["https://orcid.org/0000-0001-8712-2251"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Birgitta Benda","raw_affiliation_strings":["Pfizer, Inc, Collegeville, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer, Inc, Collegeville, Pennsylvania, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108497011","display_name":"Koshika Soma","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Koshika Soma","raw_affiliation_strings":["Pfizer Inc, Groton, Connecticut, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Groton, Connecticut, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025867925","display_name":"Lisy Wang","orcid":"https://orcid.org/0000-0003-1096-0868","observed_orcids":["https://orcid.org/0000-0003-1096-0868"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Lisy Wang","raw_affiliation_strings":["Pfizer Inc, Groton, Connecticut, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Groton, Connecticut, USA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5072429797","display_name":"Richard J. Riese","orcid":"https://orcid.org/0009-0000-3657-6229","observed_orcids":["https://orcid.org/0009-0000-3657-6229"]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Riese","raw_affiliation_strings":["Pfizer Inc, Groton, Connecticut, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc, Groton, Connecticut, USA","institution_ids":["https://openalex.org/I180857899"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5025867925"],"corresponding_institution_ids":["https://openalex.org/I180857899"],"apc_list":{"value":4870,"currency":"USD","value_usd":4870},"apc_paid":{"value":4870,"currency":"USD","value_usd":4870},"fwci":3.1101,"has_fulltext":true,"cited_by_count":173,"citation_normalized_percentile":{"value":0.94867925,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"75","issue":"5","first_page":"831","last_page":"841"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10200","display_name":"Rheumatoid Arthritis Research and Therapies","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11616","display_name":"Autoimmune and Inflammatory Disorders Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11943","display_name":"Pharmacovigilance and Adverse Drug Reactions","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tofacitinib","display_name":"tofacitinib","score":1.0},{"id":"https://openalex.org/keywords/jak-inhibitors","display_name":"JAK inhibitors","score":0.9020000100135803},{"id":"https://openalex.org/keywords/rheumatoid-arthritis","display_name":"rheumatoid arthritis","score":0.9919999837875366},{"id":"https://openalex.org/keywords/cancer","display_name":"cancer","score":0.7929999828338623},{"id":"https://openalex.org/keywords/cancer-risk","display_name":"cancer risk","score":0.5809999704360962},{"id":"https://openalex.org/keywords/lung-cancer","display_name":"lung cancer","score":0.9760000109672546},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9990000128746033},{"id":"https://openalex.org/keywords/lymphoma","display_name":"lymphoma","score":0.9789999723434448},{"id":"https://openalex.org/keywords/gastric-cancer","display_name":"gastric cancer","score":0.9610000252723694},{"id":"https://openalex.org/keywords/non-melanoma-skin-cancer","display_name":"non-melanoma skin cancer","score":0.9679999947547913},{"id":"https://openalex.org/keywords/methotrexate","display_name":"methotrexate","score":0.7360000014305115},{"id":"https://openalex.org/keywords/standardized-incidence-ratio","display_name":"standardized incidence ratio","score":0.6930000185966492},{"id":"https://openalex.org/keywords/long-term-extension-study","display_name":"long-term extension study","score":0.6340000033378601}],"concepts":[{"id":"https://openalex.org/C2778886723","wikidata":"https://www.wikidata.org/wiki/Q3530324","display_name":"Tofacitinib","level":3,"score":0.9869141578674316},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9423599243164062},{"id":"https://openalex.org/C2776233030","wikidata":"https://www.wikidata.org/wiki/Q17149812","display_name":"Janus kinase inhibitor","level":4,"score":0.8278435468673706},{"id":"https://openalex.org/C2777575956","wikidata":"https://www.wikidata.org/wiki/Q187255","display_name":"Rheumatoid arthritis","level":2,"score":0.6416726112365723},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6034175157546997},{"id":"https://openalex.org/C2777789703","wikidata":"https://www.wikidata.org/wiki/Q192102","display_name":"Skin cancer","level":3,"score":0.5356907844543457},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4588416814804077},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.44455960392951965},{"id":"https://openalex.org/C2779399171","wikidata":"https://www.wikidata.org/wiki/Q1483951","display_name":"Malignancy","level":2,"score":0.4226016700267792},{"id":"https://openalex.org/C16005928","wikidata":"https://www.wikidata.org/wiki/Q171171","display_name":"Dermatology","level":1,"score":0.34274083375930786}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001172","descriptor_name":"Arthritis, Rheumatoid","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000453","qualifier_name":"epidemiology","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D010880","descriptor_name":"Piperidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011758","descriptor_name":"Pyrroles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015994","descriptor_name":"Incidence","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D018501","descriptor_name":"Antirheumatic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D053616","descriptor_name":"Janus Kinase 3","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.1136/annrheumdis-2014-205847","doi":"https://doi.org/10.1136/annrheumdis-2014-205847","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2014-205847","pdf_url":"https://ard.bmj.com/content/annrheumdis/75/5/831.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:4853586","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4853586","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ann Rheum Dis","raw_type":"Text"},{"id":"pmid:25902789","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25902789","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the rheumatic diseases","raw_type":"Journal Article"},{"id":"pmh:oai:CiteSeerX.psu:10.1.1.858.6795","doi":null,"is_oa":false,"landing_page_url":"http://citeseerx.ist.psu.edu/viewdoc/summary?doi=10.1.1.858.6795","pdf_url":null,"source":null,"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"http://ard.bmj.com/content/early/2015/07/09/annrheumdis-2014-205847.full.pdf","raw_type":"text"},{"id":"pmh:oai:open-archive.highwire.org:annrheumdis:75/5/831","doi":null,"is_oa":false,"landing_page_url":"http://ard.bmj.com/cgi/content/short/75/5/831","pdf_url":null,"source":{"id":"https://openalex.org/S4406923041","display_name":"HighWire Press Open Archive","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"TEXT"}],"best_oa_location":{"id":"doi:10.1136/annrheumdis-2014-205847","doi":"https://doi.org/10.1136/annrheumdis-2014-205847","is_oa":true,"landing_page_url":"https://doi.org/10.1136/annrheumdis-2014-205847","pdf_url":"https://ard.bmj.com/content/annrheumdis/75/5/831.full.pdf","source":{"id":"https://openalex.org/S25650217","display_name":"Annals of the Rheumatic Diseases","issn_l":"0003-4967","issn":["0003-4967","1468-2060"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Annals of the Rheumatic Diseases","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320324471","display_name":"Universit\u00e9 Paris-Sud","ror":"https://ror.org/028rypz17"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2122950669.pdf","grobid_xml":"https://content.openalex.org/works/W2122950669.grobid-xml"},"referenced_works_count":57,"referenced_works":["https://openalex.org/W91111206","https://openalex.org/W1572054273","https://openalex.org/W1870685255","https://openalex.org/W1900969867","https://openalex.org/W1970059200","https://openalex.org/W1974321634","https://openalex.org/W1977445011","https://openalex.org/W1980827798","https://openalex.org/W1986109277","https://openalex.org/W1989574614","https://openalex.org/W1990105300","https://openalex.org/W1992934058","https://openalex.org/W2006353845","https://openalex.org/W2014330392","https://openalex.org/W2017281030","https://openalex.org/W2028672514","https://openalex.org/W2035320881","https://openalex.org/W2038992287","https://openalex.org/W2043798314","https://openalex.org/W2045789990","https://openalex.org/W2046744512","https://openalex.org/W2068561233","https://openalex.org/W2069302785","https://openalex.org/W2069871920","https://openalex.org/W2080514510","https://openalex.org/W2089548173","https://openalex.org/W2097302763","https://openalex.org/W2099046622","https://openalex.org/W2101217991","https://openalex.org/W2104388056","https://openalex.org/W2109655434","https://openalex.org/W2111624359","https://openalex.org/W2125657144","https://openalex.org/W2128600935","https://openalex.org/W2129603347","https://openalex.org/W2129948300","https://openalex.org/W2131254861","https://openalex.org/W2131882149","https://openalex.org/W2133633410","https://openalex.org/W2137071075","https://openalex.org/W2138609584","https://openalex.org/W2139672588","https://openalex.org/W2144399580","https://openalex.org/W2149447280","https://openalex.org/W2152350812","https://openalex.org/W2153414586","https://openalex.org/W2164427325","https://openalex.org/W2164858045","https://openalex.org/W2166305732","https://openalex.org/W2167404036","https://openalex.org/W2168599228","https://openalex.org/W2265836205","https://openalex.org/W2317252829","https://openalex.org/W2325670860","https://openalex.org/W2418358993","https://openalex.org/W2466954085","https://openalex.org/W6639503292"],"related_works":["https://openalex.org/W2316256464","https://openalex.org/W2332994580","https://openalex.org/W2317856915","https://openalex.org/W2555288806","https://openalex.org/W2756429445","https://openalex.org/W4411421966","https://openalex.org/W7100643244","https://openalex.org/W2553416180","https://openalex.org/W3094882380","https://openalex.org/W4366832038"],"abstract_inverted_index":{"OBJECTIVES:":[0],"Tofacitinib":[1],"is":[2],"an":[3,32],"oral":[4],"Janus":[5,22],"kinase":[6,23],"inhibitor":[7],"for":[8,178],"the":[9,18,26,38,70,192,210],"treatment":[10],"of":[11,21,28,35,154,159,195,206],"rheumatoid":[12],"arthritis":[13],"(RA).":[14],"To":[15],"further":[16],"assess":[17],"potential":[19],"role":[20],"inhibition":[24],"in":[25,209],"development":[27,42],"malignancies,":[29],"we":[30],"performed":[31],"integrated":[33],"analysis":[34],"data":[36,46],"from":[37,54,110],"tofacitinib":[39,84,160,211,220],"RA":[40,79],"clinical":[41,212],"programme.":[43],"METHODS:":[44],"Malignancy":[45],"(up":[47],"to":[48,82],"10":[49,104],"April":[50],"2013)":[51],"were":[52,80,190],"pooled":[53],"six":[55,58],"phase":[56,71,113],"II,":[57],"Phase":[59],"III":[60,74,117],"and":[61,73,116,148,175,183,204],"two":[62],"long-term":[63],"extension":[64],"(LTE)":[65],"studies":[66,100],"involving":[67],"tofacitinib.":[68],"In":[69],"II":[72,115],"studies,":[75],"patients":[76,109,196],"with":[77,89,172,197,218],"moderate-to-severe":[78,198],"randomised":[81],"various":[83],"doses":[85],"as":[86],"monotherapy":[87],"or":[88,103],"background":[90],"non-biological":[91],"disease-modifying":[92],"antirheumatic":[93],"drugs":[94],"(DMARDs),":[95],"mainly":[96],"methotrexate.":[97],"The":[98,133,152,201],"LTE":[99],"(tofacitinib":[101],"5":[102],"mg":[105],"twice":[106],"daily)":[107],"enrolled":[108],"qualifying":[111],"prior":[112],"I,":[114],"index":[118],"studies.":[119],"RESULTS:":[120],"Of":[121],"5671":[122],"tofacitinib-treated":[123],"patients,":[124],"107":[125],"developed":[126],"malignancies":[127,155,180,185,207],"(excluding":[128,181],"non-melanoma":[129],"skin":[130],"cancer":[131,139,144,150],"(NMSC)).":[132],"most":[134],"common":[135],"malignancy":[136],"was":[137],"lung":[138],"(n=24)":[140],"followed":[141],"by":[142,156],"breast":[143],"(n=19),":[145],"lymphoma":[146],"(n=10)":[147],"gastric":[149],"(n=6).":[151],"rate":[153],"6-month":[157],"intervals":[158],"exposure":[161],"indicates":[162],"rates":[163,203],"remained":[164,214],"stable":[165,215],"over":[166,216],"time.":[167],"Standardised":[168],"incidence":[169],"ratios":[170],"(comparison":[171],"Surveillance,":[173],"Epidemiology":[174],"End":[176],"Results)":[177],"all":[179],"NMSC)":[182,189],"selected":[184],"(lung,":[186],"breast,":[187],"lymphoma,":[188],"within":[191],"expected":[193],"range":[194],"RA.":[199],"CONCLUSIONS:":[200],"overall":[202],"types":[205],"observed":[208],"programme":[213],"time":[217],"increasing":[219],"exposure.":[221]},"counts_by_year":[{"year":2026,"cited_by_count":10},{"year":2025,"cited_by_count":7},{"year":2024,"cited_by_count":11},{"year":2023,"cited_by_count":17},{"year":2022,"cited_by_count":12},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":17},{"year":2019,"cited_by_count":22},{"year":2018,"cited_by_count":22},{"year":2017,"cited_by_count":25},{"year":2016,"cited_by_count":13},{"year":2015,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}